For almost 20 years, men around the world have trusted the VigRX® brand and the results they have achieved.
Product Studied: VigRX® Plus®
Published in: BMC Complementary and Alternative Medicine 2012, 12:155
Methodology: 75 men between 25-50 were randomly assigned to take either VigRX Plus® or a placebo. Each man had mild to moderate erectile dysfunction as defined by the International Index of Erectile Function (IIEF) and took two capsules twice daily of either VigRX Plus® or the placebo for 12 weeks.
Notable Findings: Subjects who took VigRX Plus® saw their IIEF erectile function scores rise ‘significantly’ compared to the placebo after 12 weeks, with an average baseline score from 16.08 (2.87) to 25.08 (4.56) on the study’s conclusion. Similar results were seen in each of the four remaining IIEF domains (orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction).
The investigator’s global assessment rated VigRX Plus® as ‘very good’ to ‘excellent’ in more than 50% of participants, compared to ‘fair’ to ‘good’ in about 25% of those who took the placebo.
VigRX Plus® was well-tolerated and more effective than placebo for improving sexual function in men.
Research Analysis by Dr. Henry S. Edelson
At your request, I have performed a review of a product called VigRX. VigRX is offered to the public as an herbal sexual enhancer. Claims related to the product relate to improved sexual function, overall greater satisfaction, and the ability to have and maintain a larger erection than normally experienced by the individual.
I have reviewed all of the ingredients listed on the supplement facts table, and I will address each one and provide a summary at the conclusion of this report. I am also attaching relevant material relating to each component, based on information from a variety of sources, as well as a full MEDLINE searches for articles appearing in the medical literature. I will address each ingredient in the order they appear on the supplement sheet (..)
It is clear to me that the formulation of VigRX has a high likelihood of achieving its stated goal of improving sexual performance, enhancing penile size when aroused, and creating greater pleaseure from the sexual act.
Two dosages of VigRX (based on the human dosage used) i.e. 15 and 30 mg/kg/D were investigated by orally fed to the adult male Sprague Dawley rats for 14 consecutive days compared with the control group receiving 1 ml. of distilled water/D.
The results were found that the body weight gained of VigRX - treated groups did not significantly differ from the control group. VigRX especially at the dosage of 30 mg/kg/D could significantly increase sex drive, erect penile size, intracavernous pressure (ICP) and sperm density in the rats.
Blood testosterone level of the VigRX treated groups and control group are not statistically different. The body weight and various organs weight i.e. penis, testes, epididymis, seminal vesicle, prostate gland, adrenal gland, spleen and pituitary gland of the VigRX - treated groups did not significantly differ from the control group except the liver and kidney weight of the VigRX - treated group significantly less than the control group.
It was concluded that the VigRX at the dosage of 30mg/kg/D could induce the high sex drive, the penile size, the penile erection and could increase the sperm density in the rat whereas VigRX had no effect on the various organs weight but had some effects on liver and kidney by decreasing the weight of both organs significantly.
The aim of this project was to investigate the long-term effects of VigRX on sexual behavior at 4, 8 and 12 - weeks of treatment, and on erect penile size, intracavernous pressure, testosterone level, sperm density, blood chemistry and some blood parameters, and related reproductive, other organ changes at 12 - week of treatment, in the adult male Sprague-Dawley rats.
It was found that VigRX at the dosage of 15mg/kg/rat/day fed to male rats for 4, 8 and 12 weeks had no effect on the body weight gained and on sexual behavior of the male rats except ejaculation latency which was significantly less than the control group.
Long term treatment of VigRX for 12 weeks could significantly increase the sperm density, the width of erect penile size and intracavernous pressure but had no effect on every organs weight i.e. penis, testes, epididymis, seminal vesicle, prostate gland, liver, kidney, adrenal gland, spleen and pituitary gland.
Long term treatment of VigRX did not have any effect on blood chemistry value, some blood parameters except the percentage of lymphocyte but long term treatment of VigRX could significantly increase the testosterone level in these rats.
Histopathological section of some organs i.e. liver, kidney and testes revealed that long term treatment of VigRX had no pathological effects on these three organs.
It was concluded that long term treatment of VigRX at the dosage of 15 mg/kg/D had no effect on body weight gained and VigRX could not induce the sexual behavior at 4, 8 and 12 - week of treatment. Long term treatment of VigRX could significantly increase the width of erect penile size, sperm density, intracavernous pressure and testosterone level but had no effects on every organs weight, blood chemistry and some blood parameters in the male rats. Long term treatment of VigRX had no pathological effects on liver, kidney and testes histology.
The aim of this project was to investigate the effects of 2 dosages of VigRX i.e. 15 and 30 mg/kg/D fed to male Sprague Dawley rats everyday for 14 consecutive days on the liver and kidney of these rats.
It was found that only VigRX at the dosage of 30 mg/kg/D could significantly decrease the liver weight. Histopathological section of both liver and kidney showed that both dosages of VigRX did not show any pathological effects on both organs when compared with the control group.
It was concluded that treatment of VigRX continuously for 14 consecutive days had no pathological effect on the liver and kidney of male Sprague Dawley rats.